Buprenorphine for Cancer Pain

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: Fox Chase Cancer Center

No Placebo Group

Prior Safety Data

Approved in 2 jurisdictions

Trial Summary

What is the purpose of this trial?This study will evaluate patients on both buprenorphine and full agonist opioids (FAO) to assess for withdrawal symptoms. Patients will be evaluated by clinicians and using validated tools to assess for pain and withdrawal. At the same time, patients will use a CPM Rx application on their phone to track medication use.

Eligibility Criteria

This trial is for adults over 18 who speak English and can consent, experiencing cancer pain rated at least 4 on a visual scale. They must be able to use a smartphone app for tracking medication and either are on or starting buprenorphine with opioids equivalent to more than 30 mg of oral morphine. Those who may become pregnant should be using contraception.

Inclusion Criteria

I am 18 years old or older.

I experience pain at a level of 4 or higher.

I am currently on or starting a specific pain medication regimen.

Treatment Details

The study tests the combination of buprenorphine with strong painkillers (opioids) in patients with significant cancer pain, monitoring for withdrawal symptoms and effectiveness in pain management through clinician evaluations and an app that tracks medication usage.

1Treatment groups

Experimental Treatment

Group I: InterventionExperimental Treatment2 Interventions

Receiving buprenorphine with short acting full agonist opioid with CPM Rx app to document medication use.

Buprenorphine is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Buprenorphine for: